Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leukemia Gene Therapy
Study results from Erasmus University broaden understanding of leukemia gene therapy
May 26th, 2009
"The Food and Drug Administration/Center for Biologics Evaluation and Research has defined that for retroviral gene therapy, the vector-producing cell, the vector preparation, and the ex vivo gene-transduced cells have to be tested for absence of replication-competent retrovirus (RCR) if the transduced cells are cultured for > 4 days. We assessed the sensitivity of the ''extended PG4(S + L-) assay'' to detect gibbon ape leukemia virus (GALV) RCR. and applied this assay to measure GALV RCR spread in retrovirally transduced T cells," scientists in Netherlands report. "To this end, T cells were expanded for 12 days after transduction with a GALV-envelope pseudo-typed...
Source: Cancer Weekly (2009-05-26)
|
